Molecular interactions of IRF4 in B cell development and malignancies

Agnarelli A, Chevassut T, Mancini EJ (2018) IRF4 in multiple myeloma-biology, disease and therapeutic target. Leuk Res 72:52–58. https://doi.org/10.1016/j.leukres.2018.07.025 Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, Boldrick JC, Sabet H, Tran T, Yu X, Powell JI, Yang L, Marti GE, Moore T, Hudson J Jr, Lu L, Lewis DB, Tibshirani R, Sherlock G, Chan WC, Greiner TC, Weisenburger DD, Armitage JO, Warnke R, Levy R, Wilson W, Grever MR, Byrd JC, Botstein D, Brown PO, Staudt LM (2000) Distinct types of diffuse large B cell lymphoma identified by gene expression profiling. Nature 403:503–511. https://doi.org/10.1038/35000501 Asslaber D, Qi Y, Maeding N, Steiner M, Denk U, Hopner JP, Hartmann TN, Zaborsky N, Greil R, Egle A (2019) B cell specific IRF4 deletion accelerates chronic lymphocytic leukemia development by enhanced tumor immune evasion. Blood. 134:1717–1729. https://doi.org/10.1182/blood.2019000973 Battistini A (2009) Interferon regulatory factors in hematopoietic cell differentiation and immune regulation. J Interf Cytokine Res 29:765–780. https://doi.org/10.1089/jir.2009.0030 Bovolenta C, Driggers PH, Marks MS, Medin JA, Politis AD, Vogel SN, Levy DE, Sakaguchi K, Appella E, Coligan JE et al (1994) Molecular interactions between interferon consensus sequence binding protein and members of the interferon regulatory factor family. Proc Natl Acad Sci U S A 91:5046–5050. https://doi.org/10.1073/pnas.91.11.5046 Brass AL, Kehrli E, Eisenbeis CF, Storb U, Singh H (1996) Pip, a lymphoid-restricted IRF, contains a regulatory domain that is important for autoinhibition and ternary complex formation with the Ets factor PU.1. Genes Dev 10:2335–2347. https://doi.org/10.1101/gad.10.18.2335 Brass AL, Zhu AQ, Singh H (1999) Assembly requirements of PU.1-Pip (IRF-4) activator complexes: inhibiting function in vivo using fused dimers. EMBO J 18:977–991. https://doi.org/10.1093/emboj/18.4.977 Bruno A, Boisselier B, Labreche K, Marie Y, Polivka M, Jouvet A, Adam C, Figarella-Branger D, Miquel C, Eimer S, Houillier C, Soussain C, Mokhtari K, Daveau R, Hoang-Xuan K (2014) Mutational analysis of primary central nervous system lymphoma. Oncotarget 5:5065–5075. https://doi.org/10.18632/oncotarget.208 Cattoretti G, Shaknovich R, Smith PM, Jack HM, Murty VV, Alobeid B (2006) Stages of germinal center transit are defined by B cell transcription factor coexpression and relative abundance. J Immunol 177:6930–6939. https://doi.org/10.4049/jimmunol.177.10.6930 Chapman MA, Lawrence MS, Keats JJ, Cibulskis K, Sougnez C, Schinzel AC, Harview CL, Brunet JP, Ahmann GJ, Adli M, Anderson KC, Ardlie KG, Auclair D, Baker A, Bergsagel PL, Bernstein BE, Drier Y, Fonseca R, Gabriel SB, Hofmeister CC, Jagannath S, Jakubowiak AJ, Krishnan A, Levy J, Liefeld T, Lonial S, Mahan S, Mfuko B, Monti S, Perkins LM, Onofrio R, Pugh TJ, Rajkumar SV, Ramos AH, Siegel DS, Sivachenko A, Stewart AK, Trudel S, Vij R, Voet D, Winckler W, Zimmerman T, Carpten J, Trent J, Hahn WC, Garraway LA, Meyerson M, Lander ES, Getz G, Golub TR (2011) Initial genome sequencing and analysis of multiple myeloma. Nature 471:467–472. https://doi.org/10.1038/nature09837 Chen W, Lam SS, Srinath H, Jiang Z, Correia JJ, Schiffer CA, Fitzgerald KA, Lin K, Royer WE Jr (2008) Insights into interferon regulatory factor activation from the crystal structure of dimeric IRF5. Nat Struct Mol Biol 15:1213–1220. https://doi.org/10.1038/nsmb.1496 Clark KL, Halay ED, Lai E, Burley SK (1993) Co-crystal structure of the HNF-3/fork head DNA-recognition motif resembles histone H5. Nature 364:412–420. https://doi.org/10.1038/364412a0 Crowther-Swanepoel D, Broderick P, Ma Y, Robertson L, Pittman AM, Price A, Twiss P, Vijayakrishnan J, Qureshi M, Dyer MJ, Matutes E, Dearden C, Catovsky D, Houlston RS (2010) Fine-scale mapping of the 6p25.3 chronic lymphocytic leukaemia susceptibility locus. Hum Mol Genet 19:1840–1845. https://doi.org/10.1093/hmg/ddq044 Di Bernardo MC, Crowther-Swanepoel D, Broderick P, Webb E, Sellick G, Wild R, Sullivan K, Vijayakrishnan J, Wang Y, Pittman AM, Sunter NJ, Hall AG, Dyer MJ, Matutes E, Dearden C, Mainou-Fowler T, Jackson GH, Summerfield G, Harris RJ, Pettitt AR, Hillmen P, Allsup DJ, Bailey JR, Pratt G, Pepper C, Fegan C, Allan JM, Catovsky D, Houlston RS (2008) A genome-wide association study identifies six susceptibility loci for chronic lymphocytic leukemia. Nat Genet 40:1204–1210. https://doi.org/10.1038/ng.219 El Chartouni C, Schwarzfischer L, Rehli M (2010) Interleukin-4 induced interferon regulatory factor (IRF) 4 participates in the regulation of alternative macrophage priming. Immunobiology 215:821–825. https://doi.org/10.1016/j.imbio.2010.05.031 Escalante CR, Yie J, Thanos D, Aggarwal AK (1998) Structure of IRF-1 with bound DNA reveals determinants of interferon regulation. Nature 391:103–106. https://doi.org/10.1038/34224 Escalante CR, Brass AL, Pongubala JM, Shatova E, Shen L, Singh H, Aggarwal AK (2002) Crystal structure of PU.1/IRF-4/DNA ternary complex. Mol Cell 10:1097–1105 Escalante CR, Nistal-Villan E, Shen L, Garcia-Sastre A, Aggarwal AK (2007) Structure of IRF-3 bound to the PRDIII-I regulatory element of the human interferon-beta enhancer. Mol Cell 26:703–716. https://doi.org/10.1016/j.molcel.2007.04.022 Fedele PL, Liao Y, Gong JN, Yao Y, Van Delft MF, Low MSY, Tai L, Herold MJ, Jackson JT, Teh CE, Tan T, O’reilly LA, Tellier J, Grigoriadis G, Huang DCS, Shi W, Nutt SL, Willis SN (2020) The transcription factor IRF4 represses proapoptotic BMF and BIM to licence multiple myeloma survival. Leukemia. 35(7):2114–2118. https://doi.org/10.1038/s41375-020-01078-0 Fujii Y, Shimizu T, Kusumoto M, Kyogoku Y, Taniguchi T, Hakoshima T (1999) Crystal structure of an IRF-DNA complex reveals novel DNA recognition and cooperative binding to a tandem repeat of core sequences. EMBO J 18:5028–5041. https://doi.org/10.1093/emboj/18.18.5028 Fujita T, Shibuya H, Hotta H, Yamanishi K, Taniguchi T (1987) Interferon-beta gene regulation: tandemly repeated sequences of a synthetic 6 bp oligomer function as a virus-inducible enhancer. Cell 49:357–367. https://doi.org/10.1016/0092-8674(87)90288-1 Furui J, Uegaki K, Yamazaki T, Shirakawa M, Swindells MB, Harada H, Taniguchi T, Kyogoku Y (1998) Solution structure of the IRF-2 DNA-binding domain: a novel subgroup of the winged helix-turn-helix family. Structure 6:491–500. https://doi.org/10.1016/s0969-2126(98)00050-1 Glasmacher E, Agrawal S, Chang AB, Murphy TL, Zeng W, Vander Lugt B, Khan AA, Ciofani M, Spooner CJ, Rutz S, Hackney J, Nurieva R, Escalante CR, Ouyang W, Littman DR, Murphy KM, Singh H (2012) A genomic regulatory element that directs assembly and function of immune-specific AP-1-IRF complexes. Science 338:975–980. https://doi.org/10.1126/science.1228309 Gupta S, Jiang M, Anthony A, Pernis AB (1999) Lineage-specific modulation of interleukin 4 signaling by interferon regulatory factor 4. J Exp Med 190:1837–1848. https://doi.org/10.1084/jem.190.12.1837 Hiscott J, Grandvaux N, Sharma S, Tenoever BR, Servant MJ, Lin R (2003) Convergence of the NF-kappaB and interferon signaling pathways in the regulation of antiviral defense and apoptosis. Ann N Y Acad Sci 1010:237–248. https://doi.org/10.1196/annals.1299.042 Honma K, Udono H, Kohno T, Yamamoto K, Ogawa A, Takemori T, Kumatori A, Suzuki S, Matsuyama T, Yui K (2005) Interferon regulatory factor 4 negatively regulates the production of proinflammatory cytokines by macrophages in response to LPS. Proc Natl Acad Sci U S A 102:16001–16006. https://doi.org/10.1073/pnas.0504226102 Kataoka K, Nagata Y, Kitanaka A, Shiraishi Y, Shimamura T, Yasunaga J, Totoki Y, Chiba K, Sato-Otsubo A, Nagae G, Ishii R, Muto S, Kotani S, Watatani Y, Takeda J, Sanada M, Tanaka H, Suzuki H, Sato Y, Shiozawa Y, Yoshizato T, Yoshida K, Makishima H, Iwanaga M, Ma G, Nosaka K, Hishizawa M, Itonaga H, Imaizumi Y, Munakata W, Ogasawara H, Sato T, Sasai K, Muramoto K, Penova M, Kawaguchi T, Nakamura H, Hama N, Shide K, Kubuki Y, Hidaka T, Kameda T, Nakamaki T, Ishiyama K, Miyawaki S, Yoon SS, Tobinai K, Miyazaki Y, Takaori-Kondo A, Matsuda F, Takeuchi K, Nureki O, Aburatani H, Watanabe T, Shibata T, Matsuoka M, Miyano S, Shimoda K, Ogawa S (2015) Integrated molecular analysis of adult T cell leukemia/lymphoma. Nat Genet 47:1304–1315. https://doi.org/10.1038/ng.3415 Lacy SE, Barrans SL, Beer PA, Painter D, Smith AG, Roman E, Cooke SL, Ruiz C, Glover P, Van Hoppe SJL, Webster N, Campbell PJ, Tooze RM, Patmore R, Burton C, Crouch S, Hodson DJ (2020) Targeted sequencing in DLBCL, molecular subtypes, and outcomes: a Haematological Malignancy Research Network report. Blood 135:1759–1771. https://doi.org/10.1182/blood.2019003535 Lohr JG, Stojanov P, Carter SL, Cruz-Gordillo P, Lawrence MS, Auclair D, Sougnez C, Knoechel B, Gould J, Saksena G, Cibulskis K, McKenna A, Chapman MA, Straussman R, Levy J, Perkins LM, Keats JJ, Schumacher SE, Rosenberg M, Multiple Myeloma Research C, Getz G, Golub TR (2014) Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy. Cancer Cell 25:91–101. https://doi.org/10.1016/j.ccr.2013.12.015 Lu R, Medina KL, Lancki DW, Singh H (2003) IRF-4,8 orchestrate the pre-B-to-B transition in lymphocyte development. Genes Dev 17:1703–1708. https://doi.org/10.1101/gad.1104803 Ma S, Pathak S, Trinh L, Lu R (2008) Interferon regulatory factors 4 and 8 induce the expression of Ikaros and Aiolos to down-regulate pre-B cell receptor and promote cell-cycle withdrawal in pre-B cell development. Blood 111:1396–1403. https://doi.org/10.1182/blood-2007-08-110106 Maffei R, Fiorcari S, Benatti S, Atene CG, Martinelli S, Zucchini P, Potenza L, Luppi M, Marasca R (2021) IRF4 modulates the response to BCR activation in chronic lymphocytic leukemia regulating IKAROS and SYK. Leukemia 35:1330–1343. https://doi.org/10.1038/s41375-021-01178-5 Mittrucker HW, Matsuyama T, Grossman A, Kundig TM, Potter J, Shahinian A, Wakeham A, Patterson B, Ohashi PS, Mak TW (1997) Requirement for the transcription factor LSIRF/IRF4 for mature B and T lymphocyte function. Science 275:540–543. https://doi.org/10.1126/science.275.5299.540 Mondala PK, Vora AA, Zhou T, Lazzari E, Ladel L, Luo X, Kim Y, Costello C, Macleod AR, Jamieson CHM, Crews LA (2021) Selective antisense oligonucleotide inhibition of human IRF4 prevents malignant myeloma regeneration via cell cycle disruption. Cell Stem Cell 28(623–636):e9. https://doi.org/10.1016/j.stem.2020.12.017 Morin RD, Mendez-Lago M, Mungall AJ, Goya R, Mungall KL, Corbett RD, Johnson NA, Severson TM, Chiu R, Field M, Jackman S, Krzywinski M, Scott DW, Trinh DL, Tamura-Wells J, Li S, Firme MR, Rogic S, Griffith M, Chan S, Yakovenko O, Meyer IM, Zhao EY, Smailus D, Moksa M, Chittaranjan S, Rimsza L, Brooks-Wilson A, Spinelli JJ, Ben-Neriah S, Meissner B, Woolcock B, Boyle M, McDonald H, Tam A, Zhao Y, Delaney A, Zeng T, Tse K, Butterfield Y, Birol I, Holt R, Schein J, Horsman DE, Moore R, Jones SJ, Connors JM, Hirst M, Gascoyne RD, Marra MA (2011) Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature 476:298–303. https://doi.org/10.1038/nature10351 Muramatsu M, Kinoshita K, Fagarasan S, Yamada S, Shinkai Y, Honjo T (2000) Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme. Cell 102:553–563. https://doi.org/10.1016/s0092-8674(00)00078- Nam S, Lim JS (2016) Essential role of interferon regulatory factor 4 (IRF4) in immune cell development. Arch Pharm Res 39:1548–1555. https://doi.org/10.1007/s12272-016-0854-1 Ochiai K, Maienschein-Cline M, Simonetti G, Chen J, Rosenthal R, Brink R, Chong AS, Klein U, Dinner AR, Singh H, Sciammas R (2013) Transcriptional regulation of germinal center B and plasma cell fates by dynamical control of IRF4. Immunity 38:918–929. https://doi.org/10.1016/j.immuni.2013.04.009 Ozato K, Tailor P, Kubota T (2007) The interferon regulatory factor family in host defense: mechanism of action. J Biol Chem 282:20065–20069. https://doi.org/10.1074/jbc.R700003200 Panne D, Maniatis T, Harrison SC (2004) Crystal structure of ATF-2/c-Jun and IRF-3 bound to the interferon-beta enhancer. EMBO J 23:4384–4393. https://doi.org/10.1038/sj.emboj.7600453 Pasqualucci L, Compagno M, Houldsworth J, Monti S, Grunn A, Nandula SV, Aster JC, Murty VV, Shipp MA, Dalla-Favera R (2006) Inactivation of the PRDM1/BLIMP1 gene in diffuse large B cell lymphoma. J Exp Med 203:311–317. https://doi.org/10.1084/jem.20052204 Paun A, Pitha PM (2007) The IRF family, revisited. Biochimie 89:744–753. https://doi.org/10.1016/j.biochi.2007.01.014 Qin BY, Liu C, Lam SS, Srinath H, Delston R, Correia JJ, Derynck R, Lin K (2003) Crystal structure of IRF-3 reveals mechanism of autoinhibition and virus-induced phosphoactivation. Nat Struct Biol 10:913–921. https://doi.org/10.1038/nsb1002 Rauch DA, Olson SL, Harding JC, Sundaramoorthi H, Kim Y, Zhou T, Macleod AR, Challen G, Ratner L (2020) Interferon regulatory factor 4 as a therapeutic target in adult T cell leukemia lymphoma. Retrovirology 17:27. https://doi.org/10.1186/s12977-020-00535-z Remesh SG, Santosh V, Escalante CR (2015) Structural studies of IRF4 reveal a flexible autoinhibitory region and a compact linker domain. J Biol Chem 290:27779–27790. https://doi.org/10.1074/jbc.M115.678789 Rossi D, Trifonov V, Fangazio M, Bruscaggin A, Rasi S, Spina V, Monti S, Vaisitti T, Arruga F, Fama R, Ciardullo C, Greco M, Cresta S, Piranda D, Holmes A, Fabbri G, Messina M, Rinaldi A, Wang J, Agostinelli C, Piccaluga PP, Lucioni M, Tabbo F, Serra R, Franceschetti S, Deambrogi C, Daniele G, Gattei V, Marasca R, Facchetti F, Arcaini L, Inghirami G, Bertoni F, Pileri SA, Deaglio S, Foa R, Dalla-Favera R, Pasqualucci L, Rabadan R, Gaidano G (2012) The coding genome of splenic marginal zone lymphoma: activation of NOTCH2 and other pathways regulating marginal zone development. J Exp Med 209:1537–1551. https://doi.org/10.1084/jem.20120904 Saito M, Gao J, Basso K, Kitagawa Y, Smith PM, Bhagat G, Pernis A, Pasqualucci L, Dalla-Favera R (2007) A signaling pathway mediating downregulation of BCL6 in germinal center B cells is blocked by BCL6 gene alterations in B cell lymphoma. Cancer Cell 12:280–292. https://doi.org/10.1016/j.ccr.2007.08.011 Schultz SC, Shields GC, Steitz TA (1991) Crystal structure of a CAP-DNA complex: the DNA is bent by 90 degrees. Science 253:1001–1007. https://doi.org/10.1126/science.1653449 Sciammas R, Li Y, Warmflash A, Song Y, Dinner AR, Singh H (2011) An incoherent regulatory network architecture that orchestrates B cell diversification in response to antigen signaling. Mol Syst Biol 7:495. https://doi.org/10.1038/msb.2011.25 Shaffer AL, Lin KI, Kuo TC, Yu X, Hurt EM, Rosenwald A, Giltnane JM, Yang L, Zhao H, Calame K, Staudt LM (2002) Blimp-1 orchestrates plasma cell differentiation by extinguishing the mature B cell gene expression program. Immunity 17:51–62. https://doi.org/10.1016/s1074-7613(02)00335-7 Shaffer AL, Emre NC, Lamy L, Ngo VN, Wright G, Xiao W, Powell J, Dave S, Yu X, Zhao H, Zeng Y, Chen B, Epstein J, Staudt LM (2008) IRF4 addiction in multiple myeloma. Nature 454:226–231. https://doi.org/10.1038/nature07064 Shukla V, Lu R (2014) IRF4 and IRF8: governing the virtues of B Lymphocytes. Front Biol (Beijing) 9:269–282. https://doi.org/10.1007/s11515-014-1318-y Shukla V, Ma S, Hardy RR, Joshi SS, Lu R (2013) A role for IRF4 in the development of CLL. Blood 122:2848–2855. https://doi.org/10.1182/blood-2013-03-492769 Sundararaj S, Seneviratne S, Williams SJ, Enders A, Casarotto MG (2021) Structural determinants of the IRF4/DNA homodimeric complex. Nucleic Acids Res 49:2255–2265. https://doi.org/10.1093/nar/gkaa1287 Tam W, Gomez M, Chadburn A, Lee JW, Chan WC, Knowles DM (2006) Mutational analysis of PRDM1 indicates a tumor-suppressor role in diffuse large B cell lymphomas. Blood 107:4090–4100. https://doi.org/10.1182/blood-2005-09-3778 Taniguchi T, Ogasawara K, Takaoka A, Tanaka N (2001) IRF family of transcription factors as regulators of host defense. Annu Rev Immunol 19:623–655. https://doi.org/10.1146/annurev.immunol.19.1.623 Tellier J, Shi W, Minnich M, Liao Y, Crawford S, Smyth GK, Kallies A, Busslinger M, Nutt SL (2016) Blimp-1 controls plasma cell function through the regulation of immunoglobulin secretion and the unfolded protein response. Nat Immunol 17:323–330. https://doi.org/10.1038/ni.3348 Tussiwand R, Lee WL, Murphy TL, Mashayekhi M, Kc W, Albring JC, Satpathy AT, Rotondo JA, Edelson BT, Kretzer NM, Wu X, Weiss LA, Glasmacher E, Li P, Liao W, Behnke M, Lam SS, Aurthur CT, Leonard WJ, Singh H, Stallings CL, Sibley LD, Schreiber RD, Murphy KM (2012) Compensatory dendritic cell development mediated by BATF-IRF interactions. Nature 490:502–507. https://doi.org/10.1038/nature11531 White BS, Lanc I, O’neal J, Gupta H, Fulton RS, Schmidt H, Fronick C, Belter EA Jr, Fiala M, King J, Ahmann GJ, Derome M, Mardis ER, Vij R, Dipersio JF, Levy J, Auclair D, Tomasson MH (2018) A multiple myeloma-specific capture sequencing platform discovers novel translocations and frequent, risk-associated point mutations in IGLL5. Blood Cancer J 8:35. https://doi.org/10.1038/s41408-018-0062-y Willis SN, Good-Jacobson KL, Curtis J, Light A, Tellier J, Shi W, Smyth GK, Tarlinton DM, Belz GT, Corcoran LM, Kallies A, Nutt SL (2014) Transcription factor IRF4 regulates germinal center cell formation through a B cell-intrinsic mechanism. J Immunol 192:3200–3206. https://doi.org/10.4049/jimmunol.1303216 Yang Y, Shaffer AL, Emre NC 3rd, Ceribelli M, Zhang M, Wright G, Xiao W, Powell J, Platig J, Kohlhammer H, Young RM, Zhao H, Yang Y, Xu W, Buggy JJ, Balasubramanian S, Mathews LA, Shinn P, Guha R, Ferrer M, Thomas C, Waldmann TA, Staudt LM (2012) Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma. Cancer Cell 21:723–737. https://doi.org/10.1016/j.ccr.2012.05.024 Yoshida S, Nakazawa N, Iida S, Hayami Y, Sato S, Wakita A, Shimizu S, Taniwaki M, Ueda R (1999) Detection of MUM1/IRF4-IgH fusion in multiple myeloma. Leukemia 13:1812–1816. https://doi.org/10.1038/sj.leu.2401563 Zehir A, Benayed R, Shah RH, Syed A, Middha S, Kim HR, Srinivasan P, Gao J, Chakravarty D, Devlin SM, Hellmann MD, Barron DA, Schram AM, Hameed M, Dogan S, Ross DS, Hechtman JF, Delair DF, Yao J, Mandelker DL, Cheng DT, Chandramohan R, Mohanty AS, Ptashkin RN, Jayakumaran G, Prasad M, Syed MH, Rema AB, Liu ZY, Nafa K, Borsu L, Sadowska J, Casanova J, Bacares R, Kiecka IJ, Razumova A, Son JB, Stewart L, Baldi T, Mullaney KA, Al-Ahmadie H, Vakiani E, Abeshouse AA, Penson AV, Jonsson P, Camacho N, Chang MT, Won HH, Gross BE, Kundra R, Heins ZJ, Chen HW, Phillips S, Zhang H, Wang J, Ochoa A, Wills J, Eubank M, Thomas SB, Gardos SM, Reales DN, Galle J, Durany R, Cambria R, Abida W, Cercek A, Feldman DR, Gounder MM, Hakimi AA, Harding JJ, Iyer G, Janjigian YY, Jordan EJ, Kelly CM, Lowery MA, Morris LGT, Omuro AM, Raj N, Razavi P, Shoushtari AN, Shukla N, Soumerai TE, Varghese AM, Yaeger R, Coleman J, Bochner B, Riely GJ, Saltz LB, Scher HI, Sabbatini PJ, Robson ME, Klimstra DS, Taylor BS, Baselga J, Schultz N, Hyman DM, Arcila ME, Solit DB, Ladanyi M, Berger MF (2017) Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat Med 23:703–713. https://doi.org/10.1038/nm.4333